This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Cytovale
Visit WebsiteCytovale is a leading US based diagnosis company pioneering a new class of biomarkers for the diagnosis of fast moving diseases such as Sepsis.
Fast results provide emergency department doctors with an immediate opportunity to decide how to proceed with treatment.
The company’s new technologies include Microfluidics, Precision Imaging and Machine Learning that will provide foundational insights into the roots of immune-mediated disease.
According to the World Health Organisation (WHO), Sepsis causes 20% of global deaths, and estimates that the life-threatening reaction to infection causes 1 in 5 deaths worldwide. Mortality from Sepsis increases as much as 8% for every hour that treatment is delayed.
Product:
Intellisep™ test
Quickly and accurately reveals immune activation at the root of Sepsis. The results are available in less than 10 minutes. The test requires a blood sample from the patient which is then processed in a benchtop instrument designed by the company to sit in hospitals’ clinical laboratories.
Subsidiaries
Portfolio
- ProAxsis
- Glycotest
- Cetromed
- PDS Biotechnology
- Vortex Biosciences
- Wanda Health
- Q-Bot
- Sofant Technologies
- PointGrab
- SageTech Medical
- Dname-iT
- Oncocidia
- Ventive
- DeepTech Recycling
- G-Tech Medical
- FOx Biosystems
- EpiBone
- Cytovale
- Longevity Biotech
- QuantalX Neuroscience
- Insight Photonics
- Nanotech Industrial Solutions
- Martlet Capital